id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-1300-0006,FDA,FDA-2026-P-1300,"Attachment 1 - RLD BELSOMRA® (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Package Insert",Supporting & Related Material,Background Material,2026-02-27T05:00:00Z,2026,2,,,2026-02-27T23:32:57Z,,0,0,09000064b91e3e19
FDA-2026-P-1300-0007,FDA,FDA-2026-P-1300,"Attachment 2 - RLD BELSOMRA® (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Approval Letter",Supporting & Related Material,Background Material,2026-02-27T05:00:00Z,2026,2,,,2026-02-27T23:33:00Z,,0,0,09000064b91e3e1a
FDA-2026-P-1300-0005,FDA,FDA-2026-P-1300,Suitability Petition Amendment from APDM Pharmaceuticals Private Limited,Other,Amendment,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T23:32:34Z,,1,0,09000064b91e3c62
FDA-2026-P-1300-0001,FDA,FDA-2026-P-1300,Suitability Petition from APDM Pharmaceuticals Private Limited,Other,Petition(s),2026-02-05T05:00:00Z,2026,2,2026-02-05T05:00:00Z,,2026-02-27T23:24:30Z,,0,0,09000064b919045a
FDA-2026-P-1300-0002,FDA,FDA-2026-P-1300,Acknowledgment Letter from FDA DMB to APDM Pharmaceuticals Private Limited,Other,Acknowledgement Letter/Receipt,2026-02-05T05:00:00Z,2026,2,2026-02-05T05:00:00Z,,2026-02-05T21:56:26Z,,0,0,09000064b919045c
FDA-2026-P-1300-0003,FDA,FDA-2026-P-1300,"Attachment 1 - Approved Drug Products with Therapeutic Equivalence Evaluations, Electronic Orange Book listing, accessed December 26, 2025",Supporting & Related Material,Background Material,2026-02-05T05:00:00Z,2026,2,,,2026-02-05T21:58:06Z,,0,0,09000064b91936e3
FDA-2026-P-1300-0004,FDA,FDA-2026-P-1300,Attachment 2 - Draft Insert Labeling for Proposed Product,Supporting & Related Material,Background Material,2026-02-05T05:00:00Z,2026,2,,,2026-02-05T21:58:09Z,,0,0,09000064b91936e4